392
Participants
Start Date
December 31, 2005
Primary Completion Date
June 30, 2010
Study Completion Date
June 30, 2010
Bupropion HCl ER
150 mg tablets po qd for 3 days and then 150 mg po bid for remainder of 9 weeks
Placebo
Placebo
Bassett Healthcare, Cooperstown
United Health Services, Johnson City
Advanced Cardiology Specialists, Scranton
Riverside Hospital, Newport News
Charleston Area Medical Center, South Charleston
Medical University of South Carolina, Charleston
Schuster Cardiology, Kettering
Southwest Cardiology, Kettering
DVA Medical Center, Oklahoma City
Parkview Medcial Center, Pueblo
Central Maine Medical Center, Lewiston
Bay Regional Medical Center, Bay City
National Heart Foundation of Bangladesh, Dhaka
Peter Lougheed Centre of the Calgary General Hospital, Calgary
University of Alberta Hospital, Edmonton
St. Boniface General Hospital, Winnipeg
New Brunswick Heart Centre, Saint Johns
Valley Regional Hospital, Kentville
The Ottawa Hospital, General Campus, Ottawa
St. Michael's Hospital, Toronto
CHA Hotel-Dieu de Levis, Lévis
Hopital Sacre-Coeur de Montreal, Montreal
Hotel-Dieu, Montreal
Montreal General Hospital, Montreal
CSSS de Sorel-Tracy, Sorel-Tracy
CSSS de la Region de Thetford, Thetford-Mines
Centre for Chronic Disease Control, New Delhi
Isfahan Cardiovascular Research Centre, Isfahan
InterActive Research and Development, Karachi
University Hospital F. Bourguiba, Sousse
Stony Brook Hospital and Medical Center, Stony Brook
Vancouver Coastal Health, Vancouver
Victoria General Hospital, Winnipeg
Hopital de la Cite de la Sante, Laval
SMBD- Jewish General Hospital, Montreal
Hopital Laval, Québec
Hopital Fleurimont, Sherbrooke
Saskatchewan Drug Research Institute, Saskatoon
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Heart and Stroke Foundation of Canada
OTHER
Mark Eisenberg
OTHER